We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Hypertrophic Cardiomyopathy
MedXY News
EnglishTag

Hypertrophic Cardiomyopathy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM
CardiologyAficamtenCPET

Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM

By MedXY|Dec 24, 2025

This substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel exercise recovery metric. It uniquely reflects cardiac hemodynamics, predicts clinical outcomes, and demonstrates significant improvement with aficamten therapy, offerin

High Prevalence and Clinical Impact of Sleep Apnea in Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort Study
CardiologyHypertrophic Cardiomyopathysleep apnea
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

High Prevalence and Clinical Impact of Sleep Apnea in Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort Study

By MedXY|Oct 9, 2025

Sleep disordered breathing affects over half of patients with hypertrophic cardiomyopathy, correlating with worsening myocardial remodeling, diastolic dysfunction, and subclinical myocardial injury, underscoring the need for clinical trials

Unveiling the Genetic Complexity of Hypertrophic Cardiomyopathy: The Impact of Intermediate Effect Variants
CardiologyHypertrophic Cardiomyopathy

Unveiling the Genetic Complexity of Hypertrophic Cardiomyopathy: The Impact of Intermediate Effect Variants

By MedXY|Oct 6, 2025

Intermediate effect genetic variants contribute significantly to hypertrophic cardiomyopathy risk and modify disease severity and outcomes, especially when coexisting with monogenic mutations.

VO2 Recovery Time as a Novel Cardiac Performance Biomarker: Insights from the SEQUOIA-HCM Trial
CardiologyAficamtencardiopulmonary exercise testing

VO2 Recovery Time as a Novel Cardiac Performance Biomarker: Insights from the SEQUOIA-HCM Trial

By MedXY|Oct 6, 2025

This article elucidates VO2T12.5% as a new, practical oxygen uptake recovery measure reflecting cardiac function and prognosis in heart failure and obstructive hypertrophic cardiomyopathy, validated in robust clinical cohorts including the

Long-Term Benefits and Safety of Mavacamten in Obstructive Hypertrophic Cardiomyopathy: Insights from the VALOR-HCM 128-Week Study
CardiologyHypertrophic CardiomyopathyMavacamten

Long-Term Benefits and Safety of Mavacamten in Obstructive Hypertrophic Cardiomyopathy: Insights from the VALOR-HCM 128-Week Study

By MedXY|Oct 3, 2025

The VALOR-HCM trial demonstrates that mavacamten sustains symptomatic improvement and significantly reduces septal reduction therapy (SRT) need over 128 weeks in severely symptomatic obstructive hypertrophic cardiomyopathy patients.

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities